ORAGENICS INC (OGEN) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US6840236094
ORAGENICS INC financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -9.36 m USD |
| EBIT | -9.38 m USD |
| Net income | -9.84 m USD |
| Diluted EPS – continuing operations | -4.56 USD |
Full history since 2003, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ORAGENICS INC
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.
More stocks
- Fortune Valley Treasures, Inc. (FVTI)
- Nexentis Technologies Inc. (NXTS)
- Presidio Property Trust, Inc. (SQFT)
- Matinas BioPharma Holdings, Inc. (MTNB)
- Cybin Inc (HELP.NE)
- HEALTHY CHOICE WELLNESS CORP. (HCWC)
- Kaya Holdings, Inc. (KAYS)
- Adagio Medical Holdings, Inc. (ADGM)
- GPO Plus, Inc. (GPOX)
- Ocean Thermal Energy Corp (CPWR)
- Sirius Media (ALSRS.PA)
- Odyssey Health, Inc. (ODYY)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.